R2therapies Oy has discovered a novel and scientifically surprising blood-based biomarker to identify people at risk of developing dementia. The company aims to to develop an in-vitro diagnostic method compatible with primary healthcare for dementia-risk screening.
-
- Founding year:
2022
-
- Development phase:
Clinical validation
-
- Funding stage:
Pre-seed
-
- Website:
–
-
- Contact person info:
ilkka.fagerlund(at)gmail.com
-
- Team members:
4
Recent Comments